Valuation: Celldex Therapeutics, Inc.

Market Cap 3.02B 2.65B 2.46B 2.26B 4.28B 289B 4.36B 29.28B 11.48B 142B 11.36B 11.11B 491B P/E 2026 *
-8.88x
P/E 2027 * -8.82x
Enterprise Value 2.44B 2.14B 1.98B 1.82B 3.45B 234B 3.52B 23.63B 9.27B 115B 9.16B 8.96B 396B EV / Sales 2026 *
926x
EV / Sales 2027 * 210x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 2014-07-29
Chief Executive Officer 64 2008-08-31
Director of Finance/CFO 55 2009-03-31
Director TitleAgeSince
Director/Board Member 64 2008-11-30
Chairman 80 2025-06-04
Director/Board Member 93 2008-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.07B
+0.44%+1.41%+4.36%+10.81% 50.73B
-1.57%-3.18%+383.82%+593.37% 39.73B
-0.14%+0.77%+27.49%-5.50% 34.69B
+1.76%-1.78%+21.44%+53.38% 33.21B
-0.06%-0.45%+2.94%+28.70% 26.76B
-1.93%-1.01% - - 16.8B
-1.49%-6.18%+63.89%+120.53% 15.37B
+0.78%+1.16%+14.69%+17.32% 13.78B
-0.97%-2.83%+10.35%-33.29% 12.85B
Average -0.35%-0.96%+66.12%+98.16% 27.1B
Weighted average by Cap. -0.18%-0.35%+81.60%+123.89%

Financials

2026 *2027 *
Net sales 2.63M 2.31M 2.14M 1.97M 3.72M 252M 3.8M 25.51M 10.01M 124M 9.89M 9.68M 428M 11.96M 10.49M 9.72M 8.94M 16.91M 1.14B 17.24M 116M 45.43M 562M 44.92M 43.94M 1.94B
Net income -330M -289M -268M -247M -467M -31.59B -476M -3.2B -1.25B -15.51B -1.24B -1.21B -53.58B -370M -325M -301M -277M -524M -35.46B -534M -3.59B -1.41B -17.41B -1.39B -1.36B -60.14B
Net Debt -584M -512M -475M -437M -826M -55.91B -842M -5.66B -2.22B -27.45B -2.19B -2.15B -94.81B -507M -445M -412M -379M -717M -48.56B -731M -4.91B -1.93B -23.85B -1.91B -1.86B -82.36B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
38.53USD
Average target price
57.53USD
Spread / Average Target
+49.32%

Quarterly revenue - Rate of surprise